MedTrace Logo

Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure

NCT01261065 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-09-26

No results posted yet for this study

Summary

The overall hypothesis of this application is that the improvement in LV ejection performance following treatment with betablockers is due, at least in part, to improvement in intrinsic myocardial contractility.

Conditions

Interventions

DRUG

carvedilol

Patients with heart failure and LVEF \< 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight \> 80 kg.

Sponsors & Collaborators

  • Michael E. DeBakey VA Medical Center

    lead FED

Principal Investigators

  • Biykem Bozkurt, MD · Michael E.DeBakey VA Medical Center, Baylor College of Medicine

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01261065 on ClinicalTrials.gov